CDK4 and obesity due to melanocortin 4 receptor deficiency: A future challenge consists in the development of novel personalized medicine to treat obesity and related diseases, repurposing some already commercialized cancer-associated therapeutic strategies such as CDK4/6 inhibitors or CDK druggable proteins that have been presented along with this review.